Media headlines about DURECT Corporation (NASDAQ:DRRX) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT Corporation earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.2785844023168 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks: Brokerages Expect DURECT Corporation (DRRX) Will Post Earnings of -$0.05 Per Share (americanbankingnews.com)
- Healthcare Stock Buy Signal: DURECT Corporation (DRRX) – Street Observer (press release) (streetobserver.com)
- Only the Technical Indicators on DURECT Corporation (DRRX) – Wall Street Morning (wallstreetmorning.com)
- Comparing DURECT Corporation (DRRX) & Atara Biotherapeutics (ATRA) (americanbankingnews.com)
- $5.09 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter (americanbankingnews.com)
Shares of DURECT Corporation (NASDAQ DRRX) opened at 1.91 on Friday. The firm’s market cap is $280.77 million. The stock has a 50 day moving average price of $1.74 and a 200 day moving average price of $1.43. DURECT Corporation has a 12-month low of $0.74 and a 12-month high of $2.17.
DURECT Corporation (NASDAQ:DRRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). The company had revenue of $4.32 million for the quarter, compared to analysts’ expectations of $5.17 million. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. On average, equities analysts expect that DURECT Corporation will post ($0.21) earnings per share for the current year.
Several research firms have recently commented on DRRX. ValuEngine raised DURECT Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of DURECT Corporation in a report on Sunday, June 25th. Finally, Stifel Nicolaus raised DURECT Corporation from a “hold” rating to a “buy” rating and increased their price objective for the company from $1.25 to $3.00 in a report on Wednesday, July 12th.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
What are top analysts saying about DURECT Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DURECT Corporation and related companies.